Semaglutide (Wegovy)

Wegovy works by mimicking GLP-1 (glucagon-like peptide-1), a hormone naturally produced in your gut after eating ^[1]. The active ingredient, semaglutide, is a modified version of this hormone designed to last much longer in your body — about a week compared to the few minutes natural GLP-1 survives ^{[1, 10]}.

When you inject Wegovy, semaglutide binds to GLP-1 receptors in several key areas of your body. In the brain, it acts on appetite-regulation centers in the hypothalamus and brainstem, reducing hunger signals and increasing feelings of fullness after smaller amounts of food ^[1]. This is the primary mechanism driving weight loss — people simply feel less hungry and more satisfied with less food.

In the digestive system, Wegovy slows the rate at which food moves from your stomach into your small intestine (a process called gastric emptying) ^[1]. This contributes to the feeling of fullness and reduces the blood sugar spikes that can trigger hunger after meals.

Wegovy also acts on the pancreas, stimulating insulin release when blood sugar is elevated and reducing glucagon secretion ^[1]. While this is the primary mechanism for blood sugar control in diabetes, it also contributes to overall metabolic improvement in people with obesity.

The SELECT cardiovascular outcomes trial, involving over 17,600 participants, demonstrated that Wegovy reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in adults with overweight or obesity and established cardiovascular disease — even in participants without diabetes ^[6]. This led to the expanded cardiovascular indication approved by the FDA in March 2024 ^[8].

At the maintenance dose of 2.4 mg weekly, clinical trials (STEP program) showed average weight loss of 15-17% of body weight over 68 weeks ^{[2, 12]}.

Starting Wegovy involves a 16-week dose escalation designed to allow your body to adjust gradually and minimize gastrointestinal side effects ^[1]. Most people start seeing noticeable weight changes after the first 2-3 months as doses increase.

During weeks 1-4, you will inject 0.25 mg weekly. This low starting dose helps your body adjust to the medication ^[1]. You may notice some decreased appetite, but significant weight loss is not expected yet.

From weeks 5-8 (0.5 mg), appetite suppression becomes more noticeable. Many people begin losing 1-2 pounds per week ^[2]. Nausea, if it occurs, is most common during these early dose increases ^[1].

Weeks 9-12 (1 mg) and weeks 13-16 (1.7 mg) continue the gradual escalation. Weight loss accelerates for most patients ^[2]. By week 16, many have lost 5-8% of their starting body weight.

At week 17 and beyond, you reach the full maintenance dose of 2.4 mg weekly. In clinical trials, participants continued losing weight through approximately week 60, with the average total loss reaching 15-17% of starting body weight ^{[2, 12]}.

Gastrointestinal side effects are most common during dose escalation periods — roughly 40-45% of participants experience some nausea ^{[1, 2]}. It typically peaks in the first 1-2 weeks after each dose increase, then improves. Eating smaller meals, avoiding greasy foods, and staying hydrated help manage symptoms.

Your healthcare provider will likely schedule regular follow-up visits every 4-12 weeks to monitor your progress, adjust treatment if needed, and check for side effects ^{[1, 16]}. Weight loss plateaus are normal and do not necessarily indicate the medication has stopped working.

Wegovy can be injected regardless of meals or time of day ^[1]. However, your dietary habits will significantly affect how well you tolerate the medication and the degree of weight loss you achieve.

High-fat and greasy foods are the most common triggers for nausea, especially during dose escalation ^[1]. Eating smaller, more frequent meals rather than large portions can reduce gastrointestinal discomfort. Foods that are bland, low in fat, and easy to digest tend to be best tolerated during the first few months.

Alcohol adds empty calories that can undermine weight management goals ^[16]. It can also worsen nausea and gastrointestinal side effects common with Wegovy ^[1]. Additionally, for patients with type 2 diabetes taking concurrent glucose-lowering medications, alcohol can increase hypoglycemia risk.

A reduced-calorie diet is part of the FDA-approved indication for Wegovy — the medication is meant to be used alongside dietary changes, not as a substitute for them ^[1]. Most clinical trials combined Wegovy with a 500-calorie-per-day deficit ^{[2, 3, 4]}. Working with a registered dietitian can help develop an eating plan that supports your weight loss while ensuring adequate nutrition.

Wegovy is available as prefilled, single-dose pens for subcutaneous injection once weekly, on the same day each week, with or without meals ^[1].

Dose escalation schedule (16 weeks total) [1]: - Weeks 1-4: 0.25 mg once weekly - Weeks 5-8: 0.5 mg once weekly - Weeks 9-12: 1 mg once weekly - Weeks 13-16: 1.7 mg once weekly - Week 17 onward: 2.4 mg once weekly (maintenance dose)

Important: The dose escalation schedule is designed to reduce gastrointestinal side effects ^[1]. Do not increase your dose faster than the schedule above. If you experience significant GI side effects during escalation, your healthcare provider may recommend staying at the current dose for an additional 4 weeks before increasing.

Dose reduction option: If the 2.4 mg maintenance dose is not tolerated, your provider may temporarily reduce to 1.7 mg for 4 weeks and then reattempt 2.4 mg. If 2.4 mg is still not tolerated, the 1.7 mg dose may be continued as the maintenance dose ^[1].

Available pen strengths: Each pen delivers one fixed dose. Pens are available in: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg ^[1].

Administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites within the same body region each week ^[1]. Do not inject into areas where the skin is tender, bruised, red, or hard.

Missed doses: If a dose is missed, administer it as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume on the next regularly scheduled day. If more than 2 weeks have passed since the last dose, contact your healthcare provider — you may need to restart from a lower dose ^[1].

Adolescent dosing (12+): The same dose escalation schedule and maintenance dose apply to adolescents aged 12 years and older with a BMI at the 95th percentile or greater for age and sex ^{[1, 7]}.

Storage: Store unused pens in the refrigerator (36-46 degrees F / 2-8 degrees C). Each pen may be stored at room temperature (up to 86 degrees F / 30 degrees C) for up to 28 days ^[1]. Do not freeze. Protect from light.

Wegovy has a list price of approximately $1,349 per month (four weekly pens) without insurance as of early 2025 ^[15]. The higher cost relative to Ozempic reflects the higher maintenance dose (2.4 mg vs. up to 2 mg) and the weight management indication.

Novo Nordisk savings programs: The WeGo by Wegovy savings card is available for commercially insured patients, potentially reducing copays to as low as $0 for eligible patients ^[13]. This card is not available for patients with government insurance (Medicare, Medicaid, TRICARE).

Insurance coverage: Coverage for Wegovy varies significantly ^[16]. Many commercial insurers now cover it for obesity treatment, though prior authorization and step therapy requirements are common. Medicare Part D generally does not cover anti-obesity medications, though the 2024 Treat and Reduce Obesity Act proposals may change this. Medicaid coverage varies by state.

Patient assistance programs: Novo Nordisk offers a Patient Assistance Program (PAP) providing Wegovy at no cost to qualifying uninsured patients meeting income requirements (generally up to 400% of the federal poverty level) ^[13].

Appeals process: If your insurance denies coverage, your healthcare provider can submit a prior authorization appeal. Letters of medical necessity that document BMI, weight-related conditions, and prior weight loss attempts can support coverage decisions.

Cost comparison: Wegovy's monthly cost is higher than many older weight-loss medications but comparable to Zepbound (tirzepatide for weight loss, approximately $1,059/month) ^[15]. The SELECT trial cardiovascular data may support broader insurance coverage over time ^{[6, 8]}.

Wegovy is contraindicated during pregnancy ^[1]. Based on animal studies, semaglutide may cause fetal harm including structural abnormalities, embryo-fetal mortality, and reduced fetal growth at exposures below the maximum recommended human dose ^[1].

Women of childbearing potential should use reliable contraception during Wegovy treatment ^[1]. Because semaglutide has a long half-life (approximately 1 week), discontinue Wegovy at least 2 months before a planned pregnancy to ensure adequate drug clearance ^{[1, 10]}.

Weight loss during pregnancy offers no benefit and may cause fetal harm ^[1]. If pregnancy is detected during treatment, discontinue Wegovy immediately and inform your healthcare provider.

It is unknown whether semaglutide passes into human breast milk ^[1]. In animal studies, semaglutide was found in the milk of lactating rats. Given the potential for adverse effects in a breastfed infant and the importance of weight management for the mother, a decision should be made in consultation with a healthcare provider about whether to discontinue nursing or discontinue Wegovy ^[1].

A pregnancy exposure registry monitors outcomes in women exposed to Wegovy during pregnancy. Healthcare providers are encouraged to report any prenatal exposure by contacting Novo Nordisk at 1-800-727-6500 ^[1].

Wegovy is manufactured exclusively by Novo Nordisk and is available only as a brand-name product ^[9]. No generic version of semaglutide injection for weight management exists.

Semaglutide is the same active ingredient found in Ozempic (type 2 diabetes) and Rybelsus (oral tablet, type 2 diabetes) ^{[1, 9]}. However, these products are not interchangeable with Wegovy. The dosing, indication, and pen configurations differ significantly. Using Ozempic off-label for weight loss is not the same as using the FDA-approved Wegovy formulation and doses studied in clinical trials ^{[2, 3, 4]}.

Novo Nordisk holds patents on semaglutide extending through 2032, with additional formulation patents potentially protecting the injectable delivery system beyond that date ^[9]. A generic injectable semaglutide for weight management is unlikely before the mid-2030s.

The FDA has issued warnings about compounded semaglutide products sold by some pharmacies and telehealth companies ^[14]. These compounded products may use semaglutide sodium salt (a different form than the FDA-approved base form), and the FDA has raised concerns about potency, sterility, and stability of these preparations ^[14].

Alternative FDA-approved injectable options for weight management include Zepbound (tirzepatide, by Eli Lilly) and Saxenda (liraglutide, by Novo Nordisk) ^{[16, 17]}. Each has a different active ingredient, dosing schedule, and efficacy profile. Discuss alternatives with your healthcare provider if Wegovy is not accessible or affordable.